Fig. 1
From: CXCL5 suppression recovers neovascularization and accelerates wound healing in diabetes mellitus
Treatment with CXCL5 neutralizing antibody upregulated VEGF/SDF-1 expression and promoted angiogenesis in late-EPCs from type 2 DM patients. Plasma levels of CXCL5 in type 2 DM patients and non-DM subjects (n = 6; A). EPCs medium levels of CXCL5 in type 2 DM patients and non-DM subjects (n = 6; B). The network formation and migration abilities were improved after the administration of CXCL5 mAb in EPCs from type 2 DM patients (n = 3; C, D). Western blotting and statistical analyses of VEGF and SDF-1 in EPCs from type 2 DM patients (n = 3; E). CXCL5 Chemokine C-X-C motif ligand 5, DM diabetes mellitus, EPC endothelial progenitor cell, mAb monoclonal antibody, SDF-1 stromal cell-derived factor 1, VEGF vascular endothelial growth factor. N represents cells cultured from n different individuals, and cells cultured from each individual were experimented for three independent experiments. The Mann–Whitney U test was used to determine statistically significant differences. *p < 0.05, **p < 0.01